Hemab Collects $157M to Target 'Underserved' Blood Diseases
Hemab, a startup with medicines in testing and development, aims to build the "ultimate coagulation disorders company," according to its CEO.
Innovation in hemophilia has progressed significantly over the last decade, with longer-lasting therapies, antibody drugs, and gene therapies improving patients' ability to control spontaneous bleeds.
However, progress in other bleeding diseases, such as Glanzmann thrombasthenia, Von Willebrand, and Factor VII deficiency, has been slower due to questions about market size and the need for complex innovations.
These disorders require more "complex innovations and bioengineering" to develop better treatment options, said Sorensen.
- Glanzmann thrombasthenia
- Von Willebrand
- Factor VII deficiency
Author's summary: Hemab raises $157M to target underserved blood diseases.
More News
- Man Utd Failed With £50 Million Mbeumo Alternative
- How to Choose and Install the Right Bathroom Ventilation System | NorthPennNow
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- State begins distributing disaster aid to residents of Western Alaska, federal aid also approved
- Zorin OS Breaks Download Record as Windows 10 Users Seek Alternatives
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- Sweden’s still ahead in the preparedness game — and now it means business
- West Indies ease past Bangladesh in first T20I